Journal of Cannabis Research
October 24, 2026
Gabriel Zoobi, Mackenzie Marco, Khalid J. Foraida et al.
Abstract: Background: Consumer- and patient-facing cannabis products are commonly labeled “indica,” “sativa,” or “hybrid” to signal expected composition or effects. We systematically reviewed whether these labels predict cannabis composition, animal effects, or human outcomes. Methods: We last searched PubMed/MEDLINE, Europe PMC, PubPsych, OpenAlex, and ClinicalTrials.gov, supplemented by...
Frontiers in Psychiatry
June 26, 2023
Simon Zhornitsky, Henrique Nunes Pereira Oliva, Laura A. Jayne et al.
12 citations
Background Ketamine and psychedelics have abuse liability. They can also induce “transformative experiences” where individuals experience enhanced states of awareness. This enhanced awareness can lead to changes in preexisting behavioral patterns which could be beneficial in the treatment of substance use disorders (SUDs). Preclinical and clinical studies suggest that ketamine and psychedelics...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
August 10, 2020
Simon Zhornitsky, Julie Pelletier, Roxane Assaf et al.
BACKGROUND Impairment in cognition is frequently associated with acute cannabis consumption. However, some questions remain unanswered as to which deficits are most prominent and which demographic groups are most vulnerable. METHODS A literature search yielded 40 experimental studies of acute administration of partial CB1 receptor agonists (i.e. cannabis, THC, and nabilone) that assessed...
Pharmaceuticals
May 21, 2012
Simon Zhornitsky, Stéphane Potvin
Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, is attracting growing attention in medicine for its anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties. However, up to this point, a comprehensive literature review of the effects of CBD in humans is lacking. The aim of the present systematic review is to examine the randomized and crossover studies that...